• KOL
    • Breast Cancer
    • Alberto Luini
    • Alberto Luini: Influence Statistics

      Alberto Luini

      Alberto Luini

      Show email address

      Division of Breast Surgery, IEO European Institute of Oncology IRCCS, Milan, Italy. | Department of Breast Surgery, IEO European Institute of Oncology IRCCS, Milan, Italy, | ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Alberto Luini:Expert Impact

      Concepts for whichAlberto Luinihas direct influence:Breast cancer,Axillary dissection,Node biopsy,Breast carcinoma,European institute,Sentinel node,Intraoperative radiotherapy,Lymph node.

      Alberto Luini:KOL impact

      Concepts related to the work of other authors for whichfor which Alberto Luini has influence:Breast cancer,Lymph node,Neoadjuvant chemotherapy,Radiation therapy,Ductal carcinoma,Axillary dissection.

      KOL Resume for Alberto Luini

      Year
      2021

      Division of Breast Surgery, IEO European Institute of Oncology IRCCS, Milan, Italy.

      2020

      Department of Breast Surgery, IEO European Institute of Oncology IRCCS, Milan, Italy,

      2019

      Division of Senology, European Institute of Oncology, 20141, Milan, Italy.

      2018

      Breast Surgery Unit, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy

      2017

      European Institute of Oncology, Division of Senology, Via G Ripamonti 435, Milan 20141, Italy

      2016

      Division of Breast Surgery, European Institute of Oncology, Via G. Ripamonti 435, 20141 Milan, Italy

      2015

      Division of Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy

      2014

      Division of Senology, Data Management, European Institute of Oncology, Via Ripamonti, 435, 20141 Milan, Italy

      2013

      Senology Division, European Institute of Oncology, Milan, Italy

      2012

      Division of Senology, European Institute of Oncology, Via Ripamonti 435, Milan, Italy

      2011

      Division of Senology, Unit of Molecular Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy

      2010

      bDivisions of Senology and

      Division of Senology, European Institute of Oncology, Milano

      University of Milan School of Medicine, Milan, Italy

      2009

      Department of Senology (EIO), Milan, Italy

      Breast Surgery,

      2008

      Breast Surgery, European Institute of Oncology, Milan, Italy

      Department of Senology, European Institute of Oncology, Milan

      2007

      Department of Senology, European Institute of Oncology, Milan, Italy

      Division of Breast Surgery, European Institute of Oncology, Milan;

      2006

      Division of Senology, Milan, Italy

      School of Medicine, University of Milan, Milan

      2005

      Division of Breast Surgery, University of Milan, Milan, Italy

      2004

      Division of Senology, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 20141, Italy

      2003

      Breast and

      Division of Pathology, European Institute of Oncology, Milan, Italy

      2002

      Divisions of Senology, European Institute of Oncology, Milan, Italy

      From the Department of Senology, European Institute of Oncology (U.V., A.L., M.A.)

      2001

      Breast Division, Istituto Europeo di Oncologia, University of Milan, Via G. Ripamonti 435, 20141 Milan, Italy

      2000

      Department of Surgery, Breast Unit (Gennari, Galimberti, Zurrida, Zerwes, Pigatto, Lunini, Veronesi) European Institute of Oncology, Milan, Italy

      1999

      Senology Department, Istituto Europeo di Oncologia, via G. Ripamonti 435, 20141 Milano Italy

      1998

      Division of Senology, Istituto Europeo di Oncologia, Via Ripamonti 435, 20121 Milan, Italy

      1997

      Division of Surgery, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy

      1996

      Istituto Europeo di Oncologia, Milano, Italy

      1995

      presently at the Istituto Europeo di Oncologia, via Ripamonti 435, 20141 Milano, Italy

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Alberto Luini is among the top experts in the world.
      Concept World rank
      approximate annual incidence #1
      lesion concentricity #1
      radiotherapy cosmetic outcome #1
      20018 cm3 #1
      nac reconstruction nsm #1
      cribriform cases #1
      questionnaires syndrome aws #1
      lrr local radiotherapy #1
      25278 years #1
      patients breast biopsy #1
      99mtchsa nanocolloids #1
      brca1 genes bcs #1
      analytic revision #1
      literature radical surgery #1
      metastases level #1
      background paget disease #1
      survival intraductal #1
      cumulative incidence cbc #1
      breast sarcoma metastatic #1
      disfiguring operation #1
      11755 cm3 #1
      staws #1
      size mastectomy #1
      proximity margins #1
      comparison radioguided excision #1
      asymmetry breasts #1
      morton studies #1
      bcs primary chemotherapy #1
      sentinel axillary #1
      radical mastectomy ductal #1
      injected activity activity #1
      quadrantectomy procedure #1
      procedures resection #1
      anastrozole concentrations combination #1
      addition anastrozole bioavailability #1
      tamoxifen anastrozole bioavailability #1
      quadrantectomy breast #1
      survival ductal #1
      standard quadrantectomy #1
      analytic overview #1
      combined systems evaluation #1
      radioguided breast surgery #1
      placebo shbg #1
      regional recurrence risk #1
      10 mastectomies #1
      aid plastic surgeon #1
      snollmethodsfrom #1
      patients breasts symmetry #1
      combination anastrozole arm #1
      wire localization meansd #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Alberto Luini

      KOL-Index: 21222

      BACKGROUND: For patients with breast cancer and metastases in the sentinel nodes, axillary dissection has been standard treatment. However, for patients with limited sentinel-node involvement, axillary dissection might be overtreatment. We designed IBCSG trial 23-01 to determine whether no axillary dissection was non-inferior to axillary dissection in patients with one or more micrometastatic (≤2 mm) sentinel nodes and tumour of maximum 5 cm.

      METHODS: In this multicentre, randomised, ...

      Known for Axillary Dissection | Sentinel Nodes | Patients Breast Cancer | Phase 3 | Aged Neoplasm
      KOL-Index: 16538

      BACKGROUND: In women with breast cancer, sentinel-lymph-node biopsy (SLNB) provides information that allows surgeons to avoid axillary-lymph-node dissection (ALND) if the SLN does not have metastasis, and has a favourable effect on quality of life. Results of our previous trial showed that SLNB accurately screens the ALN for metastasis in breast cancers of diameter 2 mm or less. We aimed to update this trial with results from longer follow-up.

      METHODS: Women with breast tumours of ...

      Known for Breast Cancer | Alnd Slnb | Node Biopsy | Staging Procedure | Negative Slns
      KOL-Index: 15843

      BACKGROUND: Intraoperative radiotherapy with electrons allows the substitution of conventional postoperative whole breast irradiation with one session of radiotherapy with the same equivalent dose during surgery. However, its ability to control for recurrence of local disease required confirmation in a randomised controlled trial.

      METHODS: This study was done at the European Institute of Oncology (Milan, Italy). Women aged 48-75 years with early breast cancer, a maximum tumour diameter ...

      Known for Intraoperative Radiotherapy | Equivalence Trial | Rate Ibtr | Breast Carcinoma | Randomised Controlled
      KOL-Index: 14999

      BACKGROUND: Sentinel node biopsy (SNB) has become a standard treatment in staging axillary lymph nodes in early breast cancer. SNB, however, is an invasive procedure and is time-consuming when the sentinel node is analysed intra-operatively. Breast cancer is frequently characterised by increased 2-fluoro-2-deoxy-D-glucose uptake and many studies have shown encouraging results in detecting axillary lymph node metastases. The aim of this study was to compare SNB and -positron emission ...

      Known for Node Biopsy | Axillary Metastases | Alnd Snb | Pet Imaging | Sentinel Lymph
      KOL-Index: 14346

      PURPOSE: The purpose of this research was to identify factors predicting response to preoperative chemotherapy.

      EXPERIMENTAL DESIGN: In a large volume laboratory using standard immunohistochemical methods, we reviewed the pretreatment biopsies and histologic specimens at final surgery of 399 patients with large or locally advanced breast cancer (cT2-T4, N0-2, M0) who were treated with preoperative chemotherapy. The incidence of pathological complete remission and the incidence of ...

      Known for Preoperative Treatment | Estrogen Receptor | Chemotherapy Patients | Breast Cancer | Pathological Complete Remission
      KOL-Index: 14186

      BACKGROUND: Routine histologic examination of axillary sentinel lymph nodes predicts axillary lymph node status and may spare patients with breast carcinoma axillary lymph node dissection. To avoid the need for two separate surgical sessions, the results of sentinel lymph node examination should be available intraoperatively. However, routine frozen-section examination of sentinel lymph nodes is liable to yield false-negative results. This study was conducted to ascertain whether ...

      Known for Intraoperative Examination | Axillary Sentinel | Lymph Nodes | Carcinoma Patients | Node Negative
      KOL-Index: 14087

      BACKGROUND: Sentinel lymph node (SLN) biopsy is used increasingly in patients with clinically lymph node negative, early-stage breast carcinoma, because it can spare axillary dissection when the sentinel lymph nodes are negative. The question arises, however, whether complete axillary lymph node dissection (ALND) also is necessary in patients with only micrometastases (< or = 2 mm in greatest dimension) in axillary SLNs. The authors carried out the current study to ascertain the risk of ...

      Known for Breast Carcinoma | Lymph Nodes | Clinical Implications | Patients Micrometastases | Sln Biopsy
      KOL-Index: 13882

      BackgroundBreast-conserving surgery has become the standard approach for about 80% of patients treated for primary breast cancer in most centres. However, mastectomy is still required in case of multicentric and/or large tumours or where recurrences occur after conservative treatment. When a total mastectomy is performed, the removal of the nipple areola complex (NAC) is a strongly debated issue. In fact, although removal of the NAC greatly increases the patient’s sensation of ...

      Known for Nac Patients | Situ Carcinoma | Breast Cancer Treatment | Sparing Mastectomy | Intra Operative Radiotherapy
      KOL-Index: 12858

      BACKGROUND: Axillary lymph-node dissection is an important staging procedure in the surgical treatment of breast cancer. However, early diagnosis has led to increasing numbers of dissections in which axillary nodes are free of disease. This raises questions about the need for the procedure. We carried out a study to assess, first, whether a single axillary lymph node (sentinel node) initially receives malignant cells from a breast carcinoma and, second, whether a clear sentinel node ...

      Known for Breast Cancer | Sentinel Node | Axillary Dissection | Frozen Sections | Lymphatic Metastasis Tests
      KOL-Index: 12795

      BACKGROUND: There is limited knowledge about prognosis of selected breast cancer subtypes among very young women.

      PATIENTS AND METHODS: We explored patterns of recurrence by age according to four immunohistochemically defined tumor subtypes: Luminal A and Luminal B (estrogen receptor positive and/or progesterone receptor positive and either human epidermal growth factor receptor 2 (HER2) positive and/or high Ki-67), HER2-positive (and) endocrine receptor absent and Triple Negative, in ...

      Known for 35 Years | Breast Cancer | Young Women | Triple Negative | Estrogen Receptors
      KOL-Index: 12733

      BACKGROUND: To assess the prognostic role of human epidermal growth factor receptor 2 (HER2) overexpression in patients with ductal carcinoma in situ (DCIS).

      PATIENTS AND METHODS: We identified patients with HER2-positive DCIS among a population of 1667 cases, prospectively diagnosed and surgically treated at the European Institute of Oncology from 1996 to 2008. Rates of subsequent DCIS or invasive cancer in HER2-positive disease were estimated. We evaluated Cumulative Incidence of In ...

      Known for Breast Cancer | Ductal Carcinoma | Estrogen Receptors | Her2 Positive | Neoplasm Recurrence
      KOL-Index: 12586

      BACKGROUND: Axillary lymph node dissection is an established component of the surgical treatment of breast cancer, and is an important procedure in cancer staging; however, it is associated with unpleasant side effects. We have investigated a radioactive tracer-guided procedure that facilitates identification, removal, and pathologic examination of the sentinel lymph node (i.e., the lymph node first receiving lymphatic fluid from the area of the breast containing the tumor) to predict ...

      Known for Sentinel Lymph Node | Breast Cancer | Axillary Dissection | Large Series | Staging Predictive
      KOL-Index: 12221

      BackgroundNon-palpable breast lesions are diagnosed frequently posing the problem of localization and removal. When such lesions are malignant, axillary node status must be determined. We report our experience using radio-guided occult lesion localization (ROLL) for locating and removing non-palpable breast lesions together with sentinel node biopsy (SNB) to assess axillary status. We call the technique SNOLL.MethodsFrom March 1997 to April 2004, 1046 consecutive patients presented ...

      Known for Sentinel Node | Breast Lesion | Noninfiltrating Carcinoma | Imaging Sensitivity | Conservative Surgery

      Key People For Breast Cancer

      Top KOLs in the world
      #1
      Ahmedin M Jemal
      united states breast cancer addis ababa
      #2
      Gabriel N Hortobagyi
      breast cancer neoadjuvant chemotherapy estrogen receptors
      #3
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      #4
      Charles M Perou
      breast cancer gene expression intrinsic subtypes
      #5
      Freddie Ian Bray
      cancer incidence nordic countries mortality rates
      #6
      Jacques Ferlay
      cancer incidence global burden latin america

      Division of Breast Surgery, IEO European Institute of Oncology IRCCS, Milan, Italy. | Department of Breast Surgery, IEO European Institute of Oncology IRCCS, Milan, Italy, | Division of Senology, European Institute of Oncology, 20141, Milan, Italy. |

    Download on the App StoreGet it on Google Play

    Copyright © 2023 KOL - Key Opinion Leaders, LLC.

    KOL does not provide medical advice, diagnosis or treatment.